Department of Pharmacy, National University of Singapore, Singapore.
Department of Pharmacy, KK Women and Children's Hospital, Singapore.
Ther Drug Monit. 2023 Aug 1;45(4):519-532. doi: 10.1097/FTD.0000000000001075. Epub 2023 Jan 10.
Conventionally, vancomycin trough levels have been used for therapeutic drug monitoring (TDM). Owing to the increasing evidence of trough levels being poor surrogates of area under the curve (AUC) and the advent of advanced pharmacokinetics software, a paradigm shift has been made toward AUC-guided dosing. This study aims to evaluate the impact of AUC-guided versus trough-guided TDM on vancomycin-associated nephrotoxicity.
A systematic review was conducted using PubMed, Embase, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Google scholar, and Cochrane library databases; articles published from January 01, 2009, to January 01, 2021, were retrieved and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Studies that evaluated trough-guided or AUC-guided vancomycin TDM and vancomycin-associated nephrotoxicity were included. Random-effects models were used to compare the differences in nephrotoxicity.
Of the 1191 retrieved studies, 57 were included. Most studies included adults and older adults (n = 47, 82.45%). The pooled prevalence of nephrotoxicity was lower in AUC-guided TDM [6.2%; 95% confidence interval (CI): 2.9%-9.5%] than in trough-guided TDM (17.0%; 95% CI: 14.7%-19.2%). Compared with the trough-guided approach, the AUC-guided approach had a lower risk of nephrotoxicity (odds ratio: 0.53; 95% CI: 0.32-0.89). The risk of nephrotoxicity was unaffected by the AUC derivation method. AUC thresholds correlated with nephrotoxicity only within the first 96 hours of therapy.
The AUC-guided approach had a lower risk of nephrotoxicity, supporting the updated American Society of Health-System Pharmacists guidelines. Further studies are needed to evaluate the optimal AUC-derivation methods and clinical utility of repeated measurements of the AUC and trough levels of vancomycin.
传统上,万古霉素谷浓度一直用于治疗药物监测(TDM)。由于越来越多的证据表明谷浓度不能很好地替代曲线下面积(AUC),并且先进的药代动力学软件的出现,已经发生了从谷浓度指导剂量到 AUC 指导剂量的范式转变。本研究旨在评估 AUC 指导与谷浓度指导 TDM 对万古霉素相关肾毒性的影响。
使用 PubMed、Embase、Web of Science、护理学和联合健康文献累积索引、Google Scholar 和 Cochrane 图书馆数据库进行系统评价;检索了 2009 年 1 月 1 日至 2021 年 1 月 1 日发表的文章,并根据系统评价和荟萃分析报告的首选项目清单进行了报告。纳入评估谷浓度或 AUC 指导的万古霉素 TDM 和万古霉素相关肾毒性的研究。采用随机效应模型比较肾毒性的差异。
在检索到的 1191 项研究中,有 57 项符合纳入标准。大多数研究纳入了成年人和老年人(n=47,82.45%)。AUC 指导 TDM 的肾毒性发生率较低[6.2%;95%置信区间(CI):2.9%-9.5%],而谷浓度指导 TDM 的肾毒性发生率较高[17.0%;95% CI:14.7%-19.2%]。与谷浓度指导方法相比,AUC 指导方法的肾毒性风险较低(比值比:0.53;95% CI:0.32-0.89)。AUC 衍生方法对肾毒性的风险没有影响。AUC 阈值仅在治疗的前 96 小时内与肾毒性相关。
AUC 指导方法的肾毒性风险较低,支持更新的美国卫生系统药师协会指南。需要进一步研究以评估 AUC 衍生方法的最佳方法和万古霉素 AUC 和谷浓度重复测量的临床实用性。